作者: Jinkuk Kim , In-Hee Lee , Hee Jin Cho , Chul-Kee Park , Yang-Soon Jung
DOI: 10.1016/J.CCELL.2015.07.013
关键词: Temozolomide 、 Regimen 、 Dacarbazine 、 Isocitrate dehydrogenase 、 Cancer research 、 Genomic Profile 、 Biology 、 Bioinformatics 、 Genome 、 Glioma 、 Somatic hypermutation
摘要: Tumor recurrence following treatment is the major cause of mortality for glioblastoma multiforme (GBM) patients. Thus, insights on evolutionary process at are critical improved patient care. Here, we describe our genomic analyses initial and recurrent tumor specimens from each 38 GBM A substantial divergence in landscape driver alterations was associated with distant appearance a tumor, suggesting that profile can mislead targeted therapies distally recurred tumor. In addition, contrast to IDH1-mutated gliomas, IDH1-wild-type primary GBMs rarely developed hypermutation temozolomide (TMZ) treatment, indicating low risk TMZ-induced these tumors under standard regimen.